RETRACTED: Rebamipide protects against experimentally induced intestinal ischemia/reperfusion-promoted liver damage: Impact on SIRT1/β-catenin/FOXO1and NFκB signaling
International Immunopharmacology · 2023
DOI: 10.1016/j.intimp.2023.110269 ↗Kurz gefasst
Zurückgezogene Publikation in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Nisreen E Elwany und 4 weiteren Autor:innen. Beteiligte Einrichtung: Lecturer of Clinical Pharmacology, Faculty of Medicine, Zagazig University, Zagazig, Egypt. Electronic address: Nisreenelwany@yahoo.com. Hauptthemen laut MEDLINE: NF-kappa B, Reperfusion Injury. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
Rebamipide (Reba) is a well-known gastroprotective agent. However, its potential protective efficacy against intestinal ischemia/reperfusion (I/R)-induced liver injury remains elusive. Therefore, this study aimed to assess the modulatory effect of Reba on SIRT1/β-catenin/FOXO1-NFκB signaling cascade. Thirty-two male Wistar albino rats were randomized into four groups: G1 (sham): rats were subjected to surgical stress without I/R, GII (I/R): rats were subjected to 60 min/4-h I/R, GIII (Reba + I/R): rats received Reba 100 mg/kg/day, p.o. for three weeks, then were subjected to 60 min/4-h I/R, and GIV (Reba + EX527 + I/R): rats received Reba (100 mg/kg/day p.o.) + EX527 (10 mg/kg/day, ip) for three weeks before I/R. Reba pretreatment decreased the serum levels of ALT and AST, improved I/R-induced histological alterations of both intestine and liver, increased hepatic Silent information regulator 1 (SIRT1) expression/content, β-catenin expression/immunoreactivity, and FOXO1 expression, while suppressed NF-κB p65 expression/protein content. In addition, Reba increased hepatic total antioxidant capacity (TAC), while suppressed malondialdehyde (MDA), tumor necrosis factor (TNFα), and caspase-3 activity. Furthermore, Reba inhibited BAX expression, while upregulated Bcl-2 expression. Reba exhibited a plausible protective effect against intestinal I/R-mediated liver injury by modulating SIRT1/β-catenin/FOXO1-NFκB signaling mechanisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lecturer of Clinical Pharmacology, Faculty of Medicine, Zagazig University, Zagazig, Egypt. Electronic address: Nisreenelwany@yahoo.com.
- Lecturer of Clinical Pharmacology, Faculty of Medicine, Zagazig University, Zagazig, Egypt. Electronic address: AAAbdelrehim@medicine.zu.edu.eg.
- Lecturer of Biochemistry, Faculty of Medicine, Zagazig University, Zagazig, Egypt. Electronic address: Nouramostafa25@yahoo.com.
- Associate professor of Medical Physiology, Faculty of Medicine, Zagazig University, Zagazig, Egypt. Electronic address: sskhaleel@medicine.zu.edu.eg.
- Lecturer of Clinical Pharmacology, Faculty of Medicine, Zagazig University, Zagazig, Egypt. Electronic address: NMMahmud@medicine.zu.edu.eg.
Zitieren
APA
Elwany, N. E., El Salem, A., Mostafa Mohamed, N., Khalil, S. S., & Mahmoud, N. M. (2023). RETRACTED: Rebamipide protects against experimentally induced intestinal ischemia/reperfusion-promoted liver damage: Impact on SIRT1/β-catenin/FOXO1and NFκB signaling. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110269
Vancouver
Elwany NE, El Salem A, Mostafa Mohamed N, Khalil SS, Mahmoud NM. RETRACTED: Rebamipide protects against experimentally induced intestinal ischemia/reperfusion-promoted liver damage: Impact on SIRT1/β-catenin/FOXO1and NFκB signaling. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110269
BibTeX
@article{Elwany2023,
author = {Elwany, Nisreen E and El Salem, Amal and Mostafa Mohamed, Noura and Khalil, Sama S and Mahmoud, Nevertyty M},
title = {RETRACTED: Rebamipide protects against experimentally induced intestinal ischemia/reperfusion-promoted liver damage: Impact on SIRT1/β-catenin/FOXO1and NFκB signaling},
journal = {International Immunopharmacology},
year = {2023},
doi = {10.1016/j.intimp.2023.110269}
}
EUVIMED